Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.

Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic.

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and ...

Those who took Ozempic or a similar drug had a 40% lower chance of overdosing on opioids and a 50% lower chance of getting ...

The future of the weight loss market might not revolve around GLP-1 drugs.

This is just a sneak peek at the thousands of consumer insights available to CivicScience clients. Discover more data. The ...

Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. Read more here.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...